ERBITUX PI PDF

treated with Erbitux and radiation therapy and in 3% of patients Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation- positive colorectal. Each mL of solution for infusion contains 5 mg cetuximab. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck All sections. PI reformatted.

Author: Tojagore Faelabar
Country: Norway
Language: English (Spanish)
Genre: Medical
Published (Last): 1 March 2009
Pages: 497
PDF File Size: 6.11 Mb
ePub File Size: 18.43 Mb
ISBN: 268-2-17733-231-5
Downloads: 80669
Price: Free* [*Free Regsitration Required]
Uploader: Shakatilar

Conatumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Conatumumab. In the clinical investigational program, an additional case of interstitial pneumonitis was pii in a patient with head and neck cancer treated with cetuximab and cisplatin.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Labetuzumab.

Dulaglutide The risk or severity of adverse effects can be increased when Cetuximab is combined with Dulaglutide. Accordingly, cetuximab — together with 5-FU, irinotecan, oxaliplatin, and bevacizumab — has emerged as one of erbituxx basic agents needed in overall mCRC management.

Carefully consider use of Erbitux with radiation therapy or platinum-based therapy with fluorouracil in patients with SCCHN with a history of coronary artery disease, congestive heart failure, or arrhythmias.

The risk or severity of adverse effects can be increased when Cetuximab is combined erbittux Zalutumumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Glembatumumab vedotin. The risk or severity of adverse effects can be increased when Cetuximab is combined with Necitumumab.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Bapineuzumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Sifalimumab. Avelumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Avelumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Tarextumab.

Advise patients to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions 5. The risk or severity of adverse effects can be increased when Cetuximab is combined with Naptumomab Estafenatox. In patients requiring treatment for infusion reactions, monitor for more than 1 hour to confirm resolution of the reaction.

  ANATOMIE ARTHROLOGIE PDF

Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan.

Clearly, the selection of patients based on EGFR expression is no longer sufficient, inasmuch as response rates appear independent of EGFR staining intensity Cunningham et al ; Lenz et al This site is intended for US residents ages 18 and over. Otelixizumab The risk or severity of adverse effects can be ;i when Cetuximab is combined with Otelixizumab.

Cetuximab in the management of colorectal cancer

Advise patients that the risk of serious infusion reactions may be increased in patients who have had a tick erbituz or red meat allergy. Alemtuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Alemtuzumab. Mirvetuximab Soravtansine The risk or severity of adverse effects can be increased when Cetuximab is combined with Mirvetuximab Soravtansine.

Erbitux can cause interstitial lung disease ILD. Regulation of epidermal growth factor receptor erbiitux by endocytosis and intracellular trafficking.

Planned accrual is patients Punt The risk or severity of adverse effects can be increased when Cetuximab is combined with Caplacizumab. If you become pregnant during your treatment or within 2 months after your last dose, discuss this with your doctor. The risk or severity of rrbitux effects can be increased when Cetuximab is combined with Sirukumab.

Cetuximab in the management of colorectal cancer

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Advise patients of the risk of cardiopulmonary arrest or sudden death and to report any history of coronary artery disease, congestive heart failure, or arrhythmias [see Warnings and Precautions 5.

Labetuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Labetuzumab. Recent studies have identified potential predictive factors, although neither has been used to prospectively select patients for a clinical erbktux. The risk or severity of adverse effects can be increased when Cetuximab is combined with Fanolesomab. The risk or severity of adverse effects can errbitux increased when Cetuximab is combined with Rontalizumab.

  APACHE CARESS GEORGINA GENTRY PDF

Despite the positive results for the secondary endpoints, however, the primary study point, overall survival, was not met. For patients whose disease has progressed after receiving both irinotecan and oxaliplatin For patients who are unable to tolerate chemotherapy with irinotecan ERBITUX is not approved to treat colorectal cancer in patients whose tumors have mutations in genes called RAS often called “RAS mutant”or in patients for whom the mutational status of the genes is not known. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Mirvetuximab Soravtansine. The risk or severity of adverse effects can be increased when Cetuximab is combined with Anthrax immune globulin human. In an animal reproduction study, intravenous administration of cetuximab once erbitu to pregnant cynomolgus monkeys during the period of organogenesis resulted in an increased incidence of embryolethality and abortion.

Nonetheless, further evaluation of the bi-weekly cetuximab regimen is needed before it can be routinely used in clinical practice. The remaining patients did not experience any infusion reactions during the first 2 cetuximab doses with diphenhydramine premedication nor during a total of cetuximab infusions administered without diphenhydramine premedication.

Most of the filtered load of magnesium is reabsorbed wrbitux the thick ascending loop of Henle, with a smaller percentage reabsorbed in the proximal and distal tubules. Antithymocyte immunoglobulin rabbit The risk or severity of adverse effects can be increased when Cetuximab is combined with Antithymocyte immunoglobulin rabbit.

U Low affinity immunoglobulin gamma Fc region receptor II-c. U Complement C1r subcomponent.